- Home
- NSAI vs PRPO Comparison
NSAI vs PRPO Comparison
Compare NSAI & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSAI | PRPO |
|---|---|---|
| Founded | 2026 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 38.3M |
| IPO Year | 2026 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NSAI | PRPO |
|---|---|---|
| Price | $9.91 | $22.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.4K | ★ 48.3K |
| Earning Date | N/A | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | $233.72 |
| Revenue Next Year | N/A | $22.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $9.86 | $18.50 |
| 52 Week High | $9.94 | $33.63 |
Technical Indicators
Market Signals| Indicator | NSAI | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 37.90 |
| Support Level | N/A | $21.93 |
| Resistance Level | $9.94 | $24.78 |
| Average True Range (ATR) | 0.01 | 1.00 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 46.31 | 23.99 |
Price Performance
Historical ComparisonAbout NSAI NorthStrive Acquisition Corp I. Class A Ordinary Shares
NorthStrive Acquisition Corp I is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.